Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH-EGFR: VRN110755 in EGFR-Mutant NSCLC
NCT07699328Phase 2Recruiting
- Sponsor
- Voronoi
- Start
- Mar 2024
- Primary completion
- Jan 2029
- Countries
- 10
01
Overview
A Phase 2 trial of VRN110755 in non-small cell lung cancer (NSCLC), sponsored by Voronoi. Started Mar 2024; status: recruiting.
02
Drugs
VRN110755
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07699328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699328.